Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Gopal

Showing results (251-260 of 429) with videos related to

Pageof 43
Sort By:
British Journal of Haematology|May 27, 2009
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphomaAndres Forero-Torres, John P Leonard, Anas Younes, et al.
Blood|February 17, 2007
Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomasAnastasia Pantelias, John M Pagel, Nathan Hedin, et al.
Journal of Clinical Pharmacology|June 12, 2013
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignanciesTae H Han, Ajay K Gopal, Radhakrishnan Ramchandren, et al.
Neurogastroenterology and Motility|March 31, 2016
Tracking gastrointestinal transit of solids in aged rats as pharmacological models of chronic dysmotilityJ E Dalziel, W Young, P Bercik, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 21, 2018
Long-Term Follow-Up of <sup>90</sup>Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell LymphomaCamille E Puronen, Ryan D Cassaday, Philip A Stevenson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2018
Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced CancerNeil H Segal, Aiwu R He, Toshihiko Doi, et al.
Blood|March 23, 2017
Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapyAjay K Gopal, Brad S Kahl, Christopher R Flowers, et al.
Cancer Medicine|November 18, 2021
Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trialSriram Balasubramanian, Brendan Hodkinson, Stephen J Schuster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2007
High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphomaAjay K Gopal, Joseph G Rajendran, Ted A Gooley, et al.
Cancer Research|January 2, 2009
Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemiaJohn M Pagel, Dana C Matthews, Aimee Kenoyer, et al.
Pageof 43

Showing results (251-260 of 429) with videos related to

Sort By:
Pageof 43
British Journal of Haematology|May 27, 2009
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphomaAndres Forero-Torres, John P Leonard, Anas Younes, et al.
Blood|February 17, 2007
Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomasAnastasia Pantelias, John M Pagel, Nathan Hedin, et al.
Journal of Clinical Pharmacology|June 12, 2013
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignanciesTae H Han, Ajay K Gopal, Radhakrishnan Ramchandren, et al.
Neurogastroenterology and Motility|March 31, 2016
Tracking gastrointestinal transit of solids in aged rats as pharmacological models of chronic dysmotilityJ E Dalziel, W Young, P Bercik, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 21, 2018
Long-Term Follow-Up of <sup>90</sup>Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell LymphomaCamille E Puronen, Ryan D Cassaday, Philip A Stevenson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2018
Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced CancerNeil H Segal, Aiwu R He, Toshihiko Doi, et al.
Blood|March 23, 2017
Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapyAjay K Gopal, Brad S Kahl, Christopher R Flowers, et al.
Cancer Medicine|November 18, 2021
Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trialSriram Balasubramanian, Brendan Hodkinson, Stephen J Schuster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2007
High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphomaAjay K Gopal, Joseph G Rajendran, Ted A Gooley, et al.
Cancer Research|January 2, 2009
Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemiaJohn M Pagel, Dana C Matthews, Aimee Kenoyer, et al.
Pageof 43